Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

INTRODUCTION: Consensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase ...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzies-Gow, Andrew, Hoyte, Flavia L., Price, David B., Cohen, David, Barker, Peter, Kreindler, James, Jison, Maria, Brooks, Christopher L., Papeleu, Peggy, Katial, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056458/
https://www.ncbi.nlm.nih.gov/pubmed/35287231
http://dx.doi.org/10.1007/s12325-022-02098-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056458/
https://www.ncbi.nlm.nih.gov/pubmed/35287231
http://dx.doi.org/10.1007/s12325-022-02098-1

Ejemplares similares